Demonstrating faster, simpler, more cost-efficient NGS workflows that turn complex agrigenomics data into practical ...

Landmark study explores the whole genomes of 1,364 breast cancers, uncovering predictive biomarkers that link genomic signatures to potential treatment outcomes and support advancing precision ...

A research consortium led by Samsung Medical Center, Seoul St. Mary's Hospital and bioinformatics partner Inocras Inc. has published the most comprehensive whole-genome breast cancer study of its kind ...

Visit NGD at Booth #712 to learn more about the NGD system, which automates both sample preparation and bioinformatics, as well as generates actionable reports for Infection Prevention teams. The NGD ...

Fintel reports that on October 20, 2025, Canaccord Genuity initiated coverage of GeneDx Holdings (NasdaqGS:WGS) with a Buy recommendation. As of September 30, 2025, the average one-year price target ...

Childhood cancers are often difficult to detect, with symptoms that may appear vague or misleading. Traditional diagnostic tools, such as biopsies and microscopic tests, often fall short when dealing ...

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, operating a CLIA/CAP-certified laboratory in San Diego, announced that its whole genome ...

Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, operating a CLIA/CAP-certified laboratory in San Diego, announced that its whole genome sequencing (WGS)-based cancer ...

Fintel reports that on July 9, 2025, Piper Sandler initiated coverage of GeneDx Holdings (NasdaqGS:WGS) with a Overweight recommendation. Analyst Price Forecast Suggests 5.44% Upside As of June 20, ...

GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ ...